Nivolumab and immune‐mediated colitis

Nivolumab is associated with a number of immune‐regulated adverse events, including immune‐mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms...

Full description

Saved in:
Bibliographic Details
Published in:Clin Case Rep
Main Authors: Walker, Heather, Brennan, Paul, Groome, Maximillian, Walsh, Shaun, Carey, Frank
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Case Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6452469/
https://ncbi.nlm.nih.gov/pubmed/30997054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2027
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items